Nanexa AB
Update in progressNANEXA.ST (Stockholm)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Nanexa AB is a pharmaceutical company developing injectable drug products across the Nordic region, Europe, Asia, and North America. It offers PharmaShell, a drug-delivery system using atomic layer deposition for controlled release. The company is developing NEX-22 (liraglutide, a GLP-1 analogue) for type 2 diabetes, NEX-18 (azacitidine) for myelodysplastic syndrome, and NEX-20 (lenalidomide) for multiple myeloma. It collaborates with Novo Nordisk and Moderna. Founded 2007, based in Uppsala, Sweden.
Company score
- Sentiment
- 0.35
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.06
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.09
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section